Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Prostate Cancer

  Free Subscription


21.09.2026

1 Am J Clin Oncol
1 Am J Surg Pathol
2 BJU Int
1 BMC Urol
3 Cancer
1 Cancer Imaging
1 Cancer Res
1 Endocrinology
3 Eur Radiol
3 Eur Urol
3 Int J Urol
2 J Urol
1 Oncogene
3 Prostate
1 Radiol Imaging Cancer
1 Urology


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Clin Oncol

  1. YU JB, Guha S, Feyisa JD, Krishnan A, et al
    The Evolution of Prostate Cancer Presentation in the United States.
    Am J Clin Oncol. 2026 Sep 15. doi: 10.1097/COC.0000000000001377.
    PubMed         Abstract available


    Am J Surg Pathol

  2. MARTIN D, Cheung CC, Yang C, Beauchamp L, et al
    Clinicopathologic Spectrum and Intraprostatic Heterogeneity of Primary Mismatch Repair-Deficient Prostate Cancer.
    Am J Surg Pathol. 2026 Sep 15. doi: 10.1097/PAS.0000000000002623.
    PubMed         Abstract available


    BJU Int

  3. MARTE JL, Hankin A, Williams M, Gulley JL, et al
    Intermittent enzalutamide in recurrent prostate cancer: testosterone kinetics and related toxicity.
    BJU Int. 2026 Sep 13. doi: 10.1111/bju.70443.
    PubMed         Abstract available

  4. BRYANT RJ, Leslie T, Laniado M, Sharma A, et al
    The PART randomised trial protocol: Partial Ablation versus Radical Treatment for prostate cancer.
    BJU Int. 2026 Sep 18. doi: 10.1111/bju.70448.
    PubMed         Abstract available


    BMC Urol

  5. BABOVIC M, Aguayo D, Wiskemann J
    Non-invasive biofeedback-assisted vs. conventional pelvic floor muscle training combined with high-effort resistance training for urinary incontinence after radical prostatectomy: a randomized controlled trial.
    BMC Urol. 2026;26:219.
    PubMed         Abstract available


    Cancer

  6. LYNCH C, Arshad M, Rajeev-Kumar G, Che Y, et al
    Long-term patient-reported outcomes and toxicity following salvage radiotherapy for biochemical recurrence after radical prostatectomy.
    Cancer. 2026;132:e70609.
    PubMed         Abstract available

  7. LAWAL IO, Jani AB, Goyal S, Abiodun-Ojo O, et al
    Effect of demographic characteristics on the outcome of prostate cancer salvage radiotherapy: Analysis from a randomized controlled trial.
    Cancer. 2026;132:e70602.
    PubMed         Abstract available

  8. LAWRENCE L
    Short-term TRT improved sexual function after radical prostatectomy in men with low-grade prostate cancer.
    Cancer. 2026;132:e70552.
    PubMed        


    Cancer Imaging

  9. BAYERL N, Appel J, Schmidt M, Cavallaro A, et al
    Diagnostic performance of AI-powered prostate MRI against biopsy ground truth: quasi-continuous risk scoring versus fixed PI-RADS thresholds.
    Cancer Imaging. 2026;26:130.
    PubMed         Abstract available


    Cancer Res

  10. MARTINEZ MJ, Blanco C, Peinetti N, Cooke M, et al
    BUB1B Mitotic Kinase Dependency Reveals CENP-E Inhibition as a Tractable Approach for Castration and Enzalutamide Resistant Prostate Cancer.
    Cancer Res. 2026 Sep 18. doi: 10.1158/0008-5472.CAN-26-0874.
    PubMed         Abstract available


    Endocrinology

  11. TORRES LM, Yates C, Bevan CL, Freeman MR, et al
    ATP-Dependent Chromatin Remodelers in Prostate Cancer Progression and Therapeutic Resistance.
    Endocrinology. 2026 Sep 16:bqag103. doi: 10.1210.
    PubMed         Abstract available


    Eur Radiol

  12. GIGANTI F, Leni R, Wagaskar V, Gandaglia G, et al
    Multicentre validation of the PRECISE scoring system for prostate MRI during active surveillance.
    Eur Radiol. 2026;36:7940-7953.
    PubMed         Abstract available

  13. KLEIBURG F, Heijmen L, Witteveen A, van Duuren K, et al
    Prognostic value of baseline PSMA PET/CT for survival in synchronous metastatic hormone-sensitive prostate cancer: towards redefining low- and high-volume disease.
    Eur Radiol. 2026 Sep 16. doi: 10.1007/s00330-026-12875.
    PubMed         Abstract available

  14. CUOCOLO R, Ponsiglione A, Agrotis G, Barrett T, et al
    Current status and future directions of AI in prostate cancer detection on MRI: a special report from the ESUR prostate MRI working group authors.
    Eur Radiol. 2026 Sep 18. doi: 10.1007/s00330-026-12836.
    PubMed         Abstract available


    Eur Urol

  15. FROEHNER M
    Re: Derya Tilki, Roderick C.N.van den Bergh, Erik Briers, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.e
    Eur Urol. 2026 Sep 16:S0302-2838(26)02374-2. doi: 10.1016/j.eururo.2026.
    PubMed        

  16. TAHA T, Longoria O, de Bono J
    Challenges of Using Circulating Tumour DNA: Insights from Advanced Prostate Cancer.
    Eur Urol. 2026 Sep 15:S0302-2838(26)02302-X. doi: 10.1016/j.eururo.2026.
    PubMed         Abstract available

  17. LONGONI M, Gandaglia G, Montorsi F
    Re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. Eur Urol. In pre
    Eur Urol. 2026 Sep 16:S0302-2838(25)04745-1. doi: 10.1016/j.eururo.2025.
    PubMed        


    Int J Urol

  18. ONOZAWA M, Shiota M, Kawai T, Sakamoto S, et al
    Impact of Clinicopathological and Institutional Factors on the Clinical Courses of Patients With Localized Prostate Cancer Initially Managed by Active Surveillance: An Analysis of Nationwide Real-World Data From Japan.
    Int J Urol. 2026;33:e70642.
    PubMed         Abstract available

  19. SEKINE Y, Arai G, Kito H, Sugimoto M, et al
    The Complementary Roles of the Prostate Health Index and Multiparametric Magnetic Resonance Imaging in Optimizing the Detection of Clinically Significant Prostate Cancer in Patients With Prostate-Specific Antigen Levels Below 10 Ng/mL.
    Int J Urol. 2026;33:e70625.
    PubMed         Abstract available

  20. SEKIGUCHI Z, Sasaki M, Matsumura K, Sato Y, et al
    Implementation of Systematic Fourth-Arm Traction and Articulating-Needle Drivers in Senhance Robotic Radical Prostatectomy: Initial Experience.
    Int J Urol. 2026;33:e70644.
    PubMed         Abstract available


    J Urol

  21. BUZOIANU MM, Ehdaie B, Vickers AJ
    Advanced stage and biochemical recurrence of grade group 1 prostate cancer after radical prostatectomy.
    J Urol. 2026 Sep 14:101097JU0000000000005309. doi: 10.1097/JU.0000000000005309.
    PubMed        

  22. CRESPO-TREVINO R, Malbas A
    Beyond the T-Score: Reconsidering the Timing of Bone-Protective Therapy in Men Receiving Androgen Deprivation Therapy for Hormone-Sensitive Prostate Cancer.
    J Urol. 2026 Sep 18:101097JU0000000000005319. doi: 10.1097/JU.0000000000005319.
    PubMed        


    Oncogene

  23. LI L, An XN, Ruan YT, Yang R, et al
    CRISPR/Cas9 screening revealed BIRC6-AS1/BIRC6 mediates abiraterone resistance via NHEJ pathway-dependent A20 degradation in prostate cancer.
    Oncogene. 2026 Sep 17. doi: 10.1038/s41388-026-03977.
    PubMed         Abstract available


    Prostate

  24. YELLANKI M, La J, Elbers DC, Do NV, et al
    Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration-Resistant Prostate Cancer.
    Prostate. 2026 Sep 17. doi: 10.1002/pros.70247.
    PubMed         Abstract available

  25. AGGARWAL P, Sood A, Satapathy S, Goyal S, et al
    [(177)Lu]Lu-PSMA-617 Plus Short-Course Priming With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Single-Arm Phase 2 Trial (Lu-PRIME).
    Prostate. 2026 Sep 13. doi: 10.1002/pros.70253.
    PubMed         Abstract available

  26. ONAL C, Erbay G, Elmali A, Demirhan B, et al
    Prognostic Value of MRI-Derived Apparent Diffusion Coefficient in Intermediate-Risk Prostate Cancer Treated With Definitive Radiotherapy.
    Prostate. 2026 Sep 13. doi: 10.1002/pros.70249.
    PubMed         Abstract available


    Radiol Imaging Cancer

  27. LU J, Cheng H, Li H, Liu K, et al
    MR Virtual Cytometry for Zone-specific Prostate Cancer Characterization with Histologic and Molecular Validation.
    Radiol Imaging Cancer. 2026;8:e250662.
    PubMed         Abstract available


    Urology

  28. BRITTON CJ, Assani K, White RE, Robinson H, et al
    Detection of Clinically-Significant Prostate Cancer on Systematic Biopsy in Patients with a PI-RADS 3-5 Lesion on MRI: Results from a Large Institutional Series.
    Urology. 2026 Sep 17:S0090-4295(26)00581-9. doi: 10.1016/j.urology.2026.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum